Mar 06, 2023 / 03:30PM GMT
Ritu Subhalaksmi Baral - TD Cowen, Research Division - MD & Senior Biotechnology Analyst
We're going to go ahead and get started. Thank you, everyone, for joining us for the Sage fireside chat at the TD Cowen Healthcare Conference this year.
With us, we have the CEO of Sage, Barry Greene, who most of you, I think, know quite well. I'm Ritu Baral, covering analyst -- moderating.
Questions and Answers:
Ritu Subhalaksmi Baral - TD Cowen, Research Division - MD & Senior Biotechnology AnalystBarry, do you want to give us just a few minutes on where we are in zuranolone's -- well, where Sage is, but also specifically where we are in zuranolone's clinical development and NDA review patent?
Barry E. Greene - Sage Therapeutics, Inc. - President, CEO & Director
Absolutely, Ritu. First of all, thanks for having us, and I appreciate the organizers for TD Cowen putting us in this enormous room that we're in. So thank you for that. It took me longer to get here than it took to get from my home to the
Trustpilot
